Patents by Inventor Stefan Hemmerich
Stefan Hemmerich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7070971Abstract: Novel glycosylsulfotransferases (GST-4?, GST-4?, and GST-6) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-4?, GST-4?, and GST-6.Type: GrantFiled: October 29, 2003Date of Patent: July 4, 2006Assignees: Syntex (U.S.A.), LLC, The Regents of the University of CaliforniaInventors: Steven Rosen, Jin Kyu Lee, Stefan Hemmerich
-
Publication number: 20050265987Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.Type: ApplicationFiled: September 1, 2004Publication date: December 1, 2005Inventors: Steven Rosen, Stefan Hemmerich, Megumi Tomita
-
Patent number: 6967093Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith.Type: GrantFiled: March 22, 2001Date of Patent: November 22, 2005Assignees: The Regents of the University of California, Syntex (U.S.A) LLCInventors: Annette Bistrup, Steven D. Rosen, Stefan Hemmerich
-
Patent number: 6933142Abstract: Mammalian glycosylsulfotransferases expressed in high endothelial cells (HEC-GLCNAC6ST) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of HEC-GLCNAC6ST or KSGal6ST, or homologues thereof.Type: GrantFiled: August 23, 2000Date of Patent: August 23, 2005Assignees: The Regents of the University of California, Syntex (USA), LLCInventors: Annette Bistrup, Steven D. Rosen, Stefan Hemmerich
-
Patent number: 6852518Abstract: Novel glycosylsulfotransferases (GST-4?, GST-4?, and GST-6) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-4?, GST-4?, and GST-6.Type: GrantFiled: June 13, 2000Date of Patent: February 8, 2005Assignees: The Regents of the University of California, Syntex (U.S.A.) LLCInventors: Steven D. Rosen, Jin Kyu Lee, Stefan Hemmerich
-
Patent number: 6844175Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications.Type: GrantFiled: November 8, 2001Date of Patent: January 18, 2005Assignees: The Regents of the University of the California, Syntex (U.S.A.) INCInventors: Annette Bistrup, Steven D. Rosen, Kirsten Tangemann, Stefan Hemmerich
-
Publication number: 20040185546Abstract: Novel glycosylsulfotransferases (GST-4&agr;, GST-4&bgr;, and GST-6) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-4&agr;, GST-4&bgr;, and GST-6.Type: ApplicationFiled: October 29, 2003Publication date: September 23, 2004Inventors: Steven D. Rosen, Jin Kyu Lee, Stefan Hemmerich
-
Publication number: 20030148920Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.Type: ApplicationFiled: December 21, 2001Publication date: August 7, 2003Inventors: Steven Rosen, Stefan Hemmerich, Megumi Tomita
-
Publication number: 20030147875Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.Type: ApplicationFiled: October 3, 2002Publication date: August 7, 2003Inventors: Steven Rosen, Stefan Hemmerich, Megumi Tomita
-
Publication number: 20020164748Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-3 or KSGal6ST, or homologues thereof.Type: ApplicationFiled: November 8, 2001Publication date: November 7, 2002Inventors: Annette Bistrup, Steven D. Rosen, Kirsten Tangemann, Stefan Hemmerich
-
Patent number: 6365365Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-3 or KSGal6ST, or homologues thereof.Type: GrantFiled: November 12, 1998Date of Patent: April 2, 2002Assignee: The Regents of the University of CaliforniaInventors: Annette Bistrup, Steven D. Rosen, Kirsten Tangemann, Stefan Hemmerich
-
Publication number: 20010051370Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith.Type: ApplicationFiled: March 22, 2001Publication date: December 13, 2001Inventors: Annette Bistrup, Steven D. Rosen, Stefan Hemmerich
-
Patent number: 6265192Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith.Type: GrantFiled: March 20, 1998Date of Patent: July 24, 2001Assignees: The Regents of the University of California, Syntex, Inc.,Inventors: Annette Bistrup, Steven D. Rosen, Stefan Hemmerich
-
Patent number: 5925349Abstract: Compositions are administered to a patient (preferably by injection and locally) to treat a variety of conditions including inflammation associated with trauma and with certain aspects of diseases such as rheumatoid arthritis, psoriasis, insulin-dependent diabetes, cutaneous lymphomas, duodenal ulcer, chronic proctitis, lymphocytic thyroiditis, hemorphagic shock, reperfusion injury during transplantation and multiple sclerosis. The compositions are pharmaceutically acceptable injectable formulations which include an active component in a pharmaceutically acceptable carrier. The active component is a chlorate or selenate which inhibits the natural biochemical sulfation process and/or a sulfatase enzyme which removes a sulfate from a specific position of a saccharide molecule which makes up a part of a natural ligand for L-selectin. Removal of the sulfate from the ligand hinders the ability of the ligand to bind to its natural receptor (i.e.Type: GrantFiled: August 19, 1997Date of Patent: July 20, 1999Assignee: The Regents Of The University Of CaliforniaInventors: Steven D. Rosen, Stefan Hemmerich, Yasuyuki Imai
-
Patent number: 5695752Abstract: Compositions are administered to a patient (preferably by injection and locally) to treat a variety of conditions including inflammation associated with trauma and with certain aspects of diseases such as rheumatoid arthritis, psoriasis, insulin-dependent diabetes, cutaneous lymphomas, duodenal ulcer, chronic proctitis, lymphocytic thyroidiris, hemorphagic shock, reperfusion injury during transplantation and multiple sclerosis. The compositions are pharmaceutically acceptable injectable formulations which include an active component in a pharmaceutically acceptable carrier. The active component is a chlorate or selenate which inhibits the natural biochemical sulfation process and/or a sulfatase enzyme which removes a sulfate from a specific position of a saccharide molecule which makes up a part of a natural ligand for L-selectin. Removal of the sulfate from the ligand hinders the ability of the ligand to bind to its natural receptor (i.e.Type: GrantFiled: June 30, 1995Date of Patent: December 9, 1997Assignee: The Regents of the University of CaliforniaInventors: Steven D. Rosen, Stefan Hemmerich, Yasuyuki Imai
-
Patent number: 5489578Abstract: Sulfated oligosaccharides which bind to L-selectin receptors and act as agonists are formulated into pharmaceutical formulations and administered by injection to treat inflammation. Compounds which act as metabolic inhibitors of carbohydrate sulfation and inhibit the sulfation of naturally occurring ligands for L-selectin receptors are administered locally by injection to alleviate and/or prevent inflammation. The sulfated oligosaccharides can be administered in combination with the chlorates and sulfatases in order to obtain a combined effect which is useful in preventing and/or alleviating inflammation. A preferred group of ligands are obtained by the hydrolysis of GlyCAM-1 by separation procedures including high pH anion exchange chromatography. The invention describes compounds that have the recognition determinants for L-selectin on GlyCAM-1 as Galactose-6-sulfate and/or N-acetylglucosamine-6-sulfate, in concert with sialic acid and fucose.Type: GrantFiled: May 2, 1996Date of Patent: February 6, 1996Assignee: The Regents of the University of CaliforniaInventors: Steven D. Rosen, Stefan Hemmerich
-
Patent number: 4996296Abstract: Substantially pure cromolyn binding protein is prepared by means of affinity chromatography of cromolyn derivatives bound to insoluble matrices. Aminocromolyn is prepared by a six-step synthesis and amine derivatives thereof are prepared by conventional means. Obtaining a compound having an amine group instead of the OH group at the 2-carbon of the propane link of cromolyn permits many kinds of reactions without interfering with the portion of the cromolyn molecule with causes its pharmacological activity. The cromolyn derivatives can be conjugated to proteins such as BSA by means of glutaraldehyde cross-linking and such conjugates can be covalently bound to agarose beads. Cromolyn binding protein can be isolated by passing lysates of RBL-2H3 cells through chromatographic columns packed with such beads. The cromolyn binding protein can be further purified by means of lectin-agarose columns.Type: GrantFiled: July 27, 1987Date of Patent: February 26, 1991Assignee: Yeda Research & Development Co., Ltd.Inventors: Israel Pecht, Stefan Hemmerich